costa_na 发表于 2014-7-4 14:41:16

Nintedanib (BIBF 1120) + Docetaxel as Second-Line Therapy in Patients With Stage IIIB/IV or Recurrent NSCLC: Results of the Phase III, Randomised,
Double-Blind LUME-Lung 1 Trial

http://www.boehringer-ingelheim.com/content/dam/internet/opu/com_EN/document/05_clinical_trials/qrcode/elcc_2014/Nintedanib_ELCC_LUME-Lung_1.pdf

costa_na 发表于 2014-7-4 14:43:19

Retrospective Evaluation of the Futility Analysis in LUME-Lung 2, a Randomised, Double-blind, Placebo-controlled Phase III Trial of Nintedanib (BIBF 1120) in Combination with Pemetrexed in NSCLC Patients Progressing after One Prior First-line Chemotherapy

costa_na 发表于 2014-7-4 14:43:57

本帖最后由 costa_na 于 2014-7-4 14:45 编辑

Identification of a Clinical Biomarker for Second-line Combination Treatment with Nintedanib in Adenocarcinoma Non-small Cell Lung Cancer (NSCLC) Patients in Two Phase III Trials

costa_na 发表于 2014-7-4 14:48:35

Phase I Study of Oral Nintedanib Combined with Docetaxel in Previously Treated Japanese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

costa_na 发表于 2014-7-4 14:50:08

Nintedanib (BIBF 1120) plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectablemalignant pleural mesothelioma—an international, multicenter, randomized, double-blind, placebo-controlled phase II study

costa_na 发表于 2014-7-4 14:57:38

Antiangiogenic-specific adverse events in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (BIBF 1120) and docetaxel

costa_na 发表于 2014-7-4 14:58:15

本帖最后由 costa_na 于 2014-7-4 23:30 编辑

TBD

mindfury 发表于 2014-7-4 14:58:47

看了一眼PDF，lume-lung 1临床试验中只有个位数比例的患者接受过一线avastin治疗。:(

目前来看，这个药在肺腺癌中是一个不错的抗血管生成药物，有希望成为穷人版的avastin。

决不放弃11 发表于 2014-7-4 17:33:42

不知YL何时有

二师兄 发表于 2014-7-4 17:36:51

决不放弃11 发表于 2014-7-4 17:33
不知YL何时有

下周
页: 1 2 [3] 4 5 6 7 8 9
查看完整版本: Nintedanib(BIBF1120)相关信息